Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Growth and development

Growth hormone therapy—is it worth the risk?

Nature Reviews Endocrinology volume 8, pages 259–260 (2012)Cite this article

Subjects

Safety is an important issue for all drugs, but even more so for treatments of non-life-threatening conditions, such as growth hormone (GH) therapy to increase adult stature. Given the almost ubiquitous expression of receptors for GH and its effector, insulin-like growth factor I, GH treatment has the potential to influence several parameters of organism biology.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Carel, J. C. et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE Study. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2011-1995.

  2. Ajuk, J. & Sheppard, M. C. Mortality following pituitary radiotherapy. Pituitary 6, 35–39 (2009).

    Google Scholar 

  3. Sävendahl, L. et al. Long-term mortality and causes of death in isolated, ghd, iss, and sga patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE Study. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2011-2882.

  4. Dekkers, O. M., von Elm, E., Algra, A., Romijn, J. A. & Vandenbroucke, J. P. How to assess the external validity of therapeutic trials: a conceptual approach. Int. J. Epidemiol. 39, 89–94 (2010).

    Article  CAS  Google Scholar 

  5. van Pareren, Y. K. et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J. Clin. Endocrinol. Metab. 88, 1119–1125 (2003).

    Article  CAS  Google Scholar 

  6. Loche, S. et al. Results of early reevaluation of growth hormone secretion in short children with apparent growth hormone deficiency. J. Pediatr. 140, 445–449 (2002).

    Article  CAS  Google Scholar 

  7. Aguiar-Oliveira, M. H. et al. Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J. Clin. Endocrinol. Metab. 95, 714–721 (2010).

    Article  CAS  Google Scholar 

  8. Guevara-Aguirre, J. et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 3, 70ra13 (2011).

    Article  Google Scholar 

  9. Gallagher, E. J. & Leroith, D. Minireview: IGF, insulin, and cancer. Endocrinology 152, 2546–2551 (2011).

    Article  CAS  Google Scholar 

  10. Albertsson-Wikland, K. et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J. Clin. Endocrinol. Metab. 93, 4342–4350 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, 21287, MD, USA

    Roberto Salvatori

Authors
  1. Roberto Salvatori
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares an association with the following company: Novo Nordisk (consultant).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salvatori, R. Growth hormone therapy—is it worth the risk?. Nat Rev Endocrinol 8, 259–260 (2012). https://doi.org/10.1038/nrendo.2012.23

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2012.23

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing